Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes
Xconomy
JUNE 3, 2016
Merck also saw some expected fruits of its 2014 big-ticket acquisition of Cubist Pharmaceuticals wither away this week, as the Supreme Court wouldn’t reverse a decision that shaved years off the patent life of the top-selling antibiotic daptomyicin (Cubicin). The drug has a list price of $69,350 per patient, per year.
62 
Let's personalize your content